Thursday 27 July, 2017
Edition: English (US)
MMJ Observer
Tag Archives: GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) happens to be a biopharmaceutical provider focusing on the discovery, development as well as the commercialization of a wide spectrum of therapeutics from its proprietary cannabinoid product platform. The...

By Jon Slotnick on Apr 19th, 2017
GW Pharmaceuticals

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) CEO Justin Gover will present at the upcoming Cowen and Company Annual Healthcare Conference on March 8, 2017. Several new drugs and therapies are being advanced at a rapidly increasing pace in the Cannabidiol...

By Emily Gibson on Mar 7th, 2017
GW Pharmaceuticals

Goldman Sachs initiated coverage on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) with a “Buy” rating and price target of $189. Four other groups lately updated their coverage. The target range as noted from the released reports is from $135...

By Emily Gibson on Jan 30th, 2017
GW Pharmaceuticals

The American Epilepsy Society’s 70th Annual Meeting was an important one for GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), as it sent off 2016 with its positive Epidiolex® (cannabidiol or CBD) Phase 3 data. The company said that the data it...


Justin Gover, the CEO of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), said that in FY2016, the company has closed three promising Phase III studies for Epidiolex in subjects with two different rare cure resistant types of childhood-onset epilepsy...

By Elizabeth Jackson on Dec 21st, 2016

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) full-year financial report was positively received. Demonstrations at the American Society of Epilepsy showcase more very promising information for epilepsy circumstances. Also, 1H2017 witnessed definite...

By Emily Gibson on Dec 7th, 2016